Hossein Ardehali, MD, PhD, has discovered that doxorubicin, an effective and commonly used anticancer drug, is causing an accumulation of iron inside of a cell’s mitochondria, resulting in heart damage.
After a heart attack, much of the damage to the heart muscle is caused by inflammatory cells that rush to the scene of the oxygen-starved tissue. But the damage is slashed in half when microparticles are injected into the blood stream within 24 hours of the attack, according to preclinical research.
The third-annual luncheon celebrating Feinberg’s named professors serves as a way to thank and honor these faculty members for their accomplishments and contributions to science, education and research.
Northwestern Medicine scientists have developed a new prognostic tool for clinicians treating patients with large B-cell lymphoma. The predictive scale enhances the widely used International Prognostic Index.
Published in the Journal of Neuroscience, a discovery by Marco Martina, MD, PhD, associate professor in Physiology, sheds new light on the selective vulnerability of cell types in preclinical models of ataxia.
Variations in DNA sequence may have a significant impact on how humans respond to dengue virus. A group of scientists from Nicaragua, the University of California-Berkeley and Feinberg will seek to uncover genetic variants that make certain people more susceptible to life-threatening forms of the infection.
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University has named Deputy Director Leonidas Platanias, MD, PhD, professor of Medicine-Hematology/Oncology, interim director, effective immediately.
Michael Ison, MD, associate professor in Medicine-Infectious Diseases and Surgery-Organ Transplantation, is co-chair of a group of scientists responsible for drafting the next edition of influenza treatment guidelines.
A group of scientists from Germany, Korea and the United States has shown how a member of the sirtuin gene family acts as a tumor suppressor to protect genome integrity.
Published in the Journal of Clinical Investigation, new research by Elizabeth Eklund, MD, points toward an alternative approach to treating the inherited and devastating bone marrow condition Fanconi anemia.